Receiving a Notice of Allowance for a patent from the European Patent Office is a significant regulatory milestone that can lead to market expansion and increased investor confidence. For Can-Fite BioPharma, this development not only validates the company's research and development efforts but also potentially opens up a new therapeutic area for its pipeline. Given the specific mention of diabetics unable to use current drugs, this patent positions CF602 as a novel solution in the erectile dysfunction market, likely leading to positive investor sentiment and a potential increase in stock price in the short term.